Amylase α-2A Autoantibodies: Novel Marker of Autoimmune Pancreatitis and Fulminant Type 1 Diabetes Mellitus

Toyoshi Endo*, Soichi Takizawa*, Shoichiro Tanaka*, Masashi Takahashi*, Hideki Fujii†, Terumi Kamisawa‡ and Tetsuro Kobayashi*

*Third Department of Internal Medicine and †First Department of Surgery
Interdisciplinary Graduate School of Medicine and Engineering
University of Yamanashi, Chuo City, Yamanashi 409-3898, Japan
‡Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan

Corresponding author:
Toyoshi Endo, MD
Third Department of Internal Medicine
Interdisciplinary Graduate School of Medicine and Engineering
University of Yamanashi, Chuo City, Yamanashi 409-3898, Japan
E-mail: endot@yamanashi.ac.jp

ABSTRACT

Objective: The pathogenesis of autoimmune pancreatitis (AIP) and fulminant type 1 diabetes (FT1DM) remains unclear, although it is known that immune-mediated processes severely compromise the endocrine and exocrine functions in both diseases.

Methods: We have screened a λTriplEx2 human pancreas cDNA library with serum from a patient with AIP and obtained positive clones. Sequence analysis revealed that seven out of 10 clones were identical to human amylase α-2A. Using a recombinant C-terminal amylase α-2A protein, we developed an enzyme-linked immunosorbent assay system to detect autoantibodies against human amylase α-2A.

Results: All 15 serum samples from patients with AIP recognized the recombinant protein, while sera from 25 patients with chronic alcoholic pancreatitis and sera from 25 patients with a pancreas tumor did not. Interestingly, 88% (15/17) of patients with FT1DM were positive for an autoantibody against amylase α-2A. These antibodies were detected in 21% of patients with acute-onset type 1 diabetes (AT1DM, 9/42) and 6% of type 2 diabetic patients (4/67).

Conclusions: These results suggest that an autoantibody against amylase α-2A is a novel diagnostic marker for both AIP and FT1DM, and that clinically and immunologically, AIP and FT1DM are closely related.
Recently, autoimmune pancreatitis (AIP), a unique form of chronic pancreatitis, has been reported as a discrete disease entity (1). It is characterized by 1) irregular narrowing of the main pancreatic duct and swelling of the pancreas, both of which are due to abundant lymphoplasmacytic inflammation to the exocrine pancreas (2); 2) the increased serum level of IgG and IgG4; 3) positive autoantibodies such as lactoferrin (LF) autoantibody or carbonic anhydrase II (CAII) autoantibody (3, 4); and 4) a high prevalence of diabetes mellitus with complications (5).

We recently reported that a high proportion of pancreatic islets as well as exocrine pancreatic tissues were infiltrated by CD4+ or CD8+ T-lymphocytes in the inflammatory process, which might induce diabetes in AIP (5). In addition, treatment with prednisolone (PSL) improved insulin secretion and glycemic control in AIP patients (6). These data support the concept that autoimmune mechanism(s) play a pivotal role in the destruction of the endocrine as well as exocrine pancreas in AIP patients with diabetes.

Clinically, the most common initial symptom of AIP is jaundice, but in some patients, no symptoms or only mild symptoms, frequently without acute attacks of pancreatitis, may be present (7). It is difficult to distinguish AIP from other types of chronic pancreatitis or cancer of the pancreatic head (8). In such cases, detection of autoantibodies is useful for diagnosing AIP, but a proportion of patients with AIP are negative for autoantibodies against LF and CAII (3, 4).

We encountered an AIP patient whose serum IgG and IgG4 levels were 3498 mg/dl and 2430 mg/dl, respectively. It has been reported that median levels (5th, 95th percentiles) of IgG and IgG4 from patients with AIP were 2389 mg/dl (1349, 4310), and 742 mg/dl (265, 1150), respectively (9), so high concentrations of IgG in this case prompted us to search for new autoantigens associated with AIP. We also searched for the presence or absence of new autoantibodies in patients with abrupt onset and severe ketoacidosis-prone type 1 diabetes (called fulminant type 1 diabetes (10, 11) (FT1DM)), which involve the exocrine pancreas as well as endocrine pancreas.

**RESEARCH DESIGN AND METHODS**

**Subjects.** Serum used for screening the human pancreas cDNA library was obtained from a 67-year-old male patient...
(A.O.), admitted to our hospital complaining of slight abdominal pain and jaundice. Computed tomography revealed an enlarged pancreas, and laboratory findings showed high concentrations of IgG and IgG4. Tests for anti-LF and anti-CAII antibodies were both positive, but negative for antinuclear antibody, anti-mitochondrial antibody, and rheumatoid factor.

Additional AIP sera were obtained from 14 newly diagnosed patients at University of Yamanashi Hospital and Toranomon Hospital, Tokyo, Japan. Diagnosis of AIP was based on criteria proposed by the Japan Pancreas Society (12). Our 15 patients filled criteria 1 (narrowing of the main pancreatic duct or enlargement of pancreas by imaging studies), together with criteria 2 (high serum $\gamma$ globulin, IgG, or IgG4, or the presence of autoantibodies such as anti-nuclear antibodies and rheumatoid factor) and/or criteria 3 (marked interlobular fibrosis and prominent infiltration of lymphocytes and plasma cells in the periductal area). Serum samples were taken from 25 patients with chronic alcoholic pancreatitis, who were diagnosed according to a history of alcohol abuse, impaired exocrine pancreatic function, and the presence of calcified precipitates in the pancreas by imaging studies (Japan Pancreas Society, criteria for chronic pancreatitis 2001 (13)). Twenty-five serum samples were recruited from patients with pancreas tumor [cancer (n = 8) and intraductal papillary mucinous tumor (IPMT, n = 17)]. FT1DM (n = 17, 13 cases at the onset and four cases after onset) was diagnosed by criteria (fasting C-peptide $\leq 0.033$ nmol/l and HbA$_{1c}$ is $\leq 8.0\%$ or $\Sigma$C-peptide $\leq 0.540$ nmol/l and HbA$_{1c}$ is $\leq 8.0\%$) as reported previously (14,15). FT1DM associated with pregnancy (16) was excluded from the present study. AT1DM (n = 42, (13)) and type 2 diabetes (T2DM) (n = 67) were also recruited. The patients’ clinical characteristics are summarized in Table 1. Serum from patients with Hashimoto’s thyroiditis (n = 47) were also studied. Diagnosis of the disease was made by elastic goiter and autoantibodies against both thyroglobulin and thyroid peroxidase. Control sera were obtained from 100 (59 male and 41 female) healthy volunteers.

**Immunoscreening.** The $\lambda$TriplEx2 human pancreas large insert cDNA library (HL5517u) and *E.coli* XL-1 competent cells were obtained from BD Biosciences Clontech (Palo Alto, CA). The plaques on the plate were transferred to nitrocellulose filters presoaked with 10 mM
isopropyl-\(\beta\)-D-thiogalactopyranoside (IPTG), washed with Tris-buffered saline containing 0.05% Tween 20 (TBST), and blocked with TBST containing 1% bovine serum albumin. The filters were incubated overnight at 4 °C with the sera from the patient with AIP (A.O.) at a dilution of 1:500. After washing four times with TBST, the filters then reacted with goat horseradish peroxidase-conjugated anti-human IgG (American Qualex, San Clemente, CA) at a dilution of 1:2000 for 30 min at room temperature. The filters were also washed four times with TBST; positive reaction was detected with 3,3’-diaminobenzidine.

**Preparation of the recombinant human AMY-2A.** A cDNA fragment of the positive clone was amplified by PCR with the sense primer, 5’-ATGGGGATCCCTTGGGTTTCGTAC CTTCTGACAGA, and anti-sense primer, 5’-CTTCGAATTCCAATTTAGATTAC GTGAATTGC. The PCR product was digested with BamHI and EcoRI, and then ligated into pTrc His B (Invitrogen Co., Carlsbad, CA). After sequencing, the plasmid was transfected into *E. coli* BL-21 (Novagen Co., Darmstadt, Germany). The production of the recombinant protein was inducted with 1 mM IPTG, and purified by His Bond column chromatography.

**Western blot analysis.** The 0.1% SDS-15% polyacrylamide gel electrophoresis and transferring onto the nitrocellulose membrane was carried out as previously described (17) with slight modifications as follows: the membrane was blocked with 5% skim milk and 5% goat serum in TBS, and then incubated with sera from the patients with AIP (1:500) overnight at 4 °C. After washing five times with TBST, the membrane was reacted with goat horseradish peroxidase-conjugated anti-human IgG (1:2000) for 30 min at room temperature. Positive reaction was detected by the same way as described in “immunoscreening”.

**In vitro translation and immunoprecipitation.** A cDNA fragment of AMY-2A was amplified by PCR with the sense primer, 5’-ATGGGGATCCATGTGGGGTTTCGTAC CTTCTGACAGA, and anti-sense primer, 5’-CTTCGAATTCCAATTTAGATTAC GTGAATTGC, which added an ATG codon at the N-terminus. The PCR product was digested with BamHI and EcoRI, and then ligated into pcDNA3.1. \(^{35}\)S labeled human AMY-2A was prepared with PROTEIN script II (Ambion, Austin, TX) and \([^{35}\text{S}]\) methionine (GE Healthcare, Piscataway, NJ). \(^{35}\)S labeled AMY-2A was
incubated with patients’ sera (×100) or anti-human amylase antibody (×100, sc-12821, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in 200 μl of phosphate-buffered saline (PBS) containing 1% bovine serum albumin at 4 °C overnight, with 10 μl of GammaBind G Sepharose (GE Healthcare) added. After further incubation at room temperature for 60 min, the mixtures were centrifuged at 10,000 rpm for 5 min. The pellets were washed three times with PBS containing 0.05% Tween 20 (PBST). Final pellets were directly counted or dissolved with 10 mM Tris-HCl (pH. 6.8) containing 0.1% SDS, boiled for 3 min, and loaded onto a 0.1% SDS-15% polyacrylamide gel.

Enzyme-linked immunosorbent Assay (ELISA) for detecting autoantibody against human AMY-2A. Autoantibody against human AMY-2A was measured by ELISA using methods previously described (5). In brief, a microtiter plate (Coster 3590, Corning Inc., Horseheads, NY) was coated with 50 μl of 0.1 μg of recombinant human AMY-2A overnight at 4 °C. After washing the plate three times with PBST, the plate was incubated with 200 μl of 1% bovine serum albumin in PBS for 30 min. Next, the patients’ sera were tested in triplicate at dilutions of 1:200 in 1% BSA for 1 h. The bound antibody was specially reacted with goat horseradish peroxidase-conjugated anti-human IgG (1:2000) in 1% BSA for 30 min at room temperature. After washing, the plate was incubated with 100 μl of 1-Step Slow TMB-ELISA (PIERCE, IL) for 30 min. The reaction was terminated by adding 100 μl of 1 M H2SO4, and absorbance was determined at an optical density of 450 nm. Intra- and inter-assay variations (C.V. (%)) , determined with the same lot of 5 ELISA plates, were 4.28 and 7.72, respectively.

Ethics. An ethical committee approved all study protocols, and patients gave informed consent.

Statistical analysis. Statistical analysis was carried out using Fisher’s exact test (JMP, Cary, NC), in which we considered statistically significant if p values were < 0.05. ROC analysis was carried out with MedCalc (MedCalc Software, Mariakerke, Belgium).

RESULTS
Cloning of cDNAs from human pancreas. We completely screened 2 × 10⁴ plaques with the AIP patient’s serum (A.O.), and obtained 10 positive clones. Nucleotide sequencing of the insert cDNAs and a subsequent homology search revealed that seven out of 10 clones were identical to human Amylase-2A (AMY-2A). When
compared to the nucleotide sequence of the human AMY-2A cloned by Wise et al. (18), four out of seven clones contained the full coding sequence, while the 5’ ends of the other three clones started from +61, +799, and +897 bp (A in ATG is designated as +1) (Fig. 1). Other non-amylase clones were those of the housekeeping genes, such as the heat shock protein and the nuclear protein.

**Western blot analysis, immunoprecipitation and ELISA system for detecting anti human AMY-2A.** Since IgG from the AIP patient used for screening recognized four different lengths of human AMY-2A clones, we hypothesized that the regions shared by these four clones, from codons 299 to 512, might contain a common epitope for the patient’s IgG (Fig. 1). Therefore, we produced histidine tagged human AMY-2A from codons 299 to 512 (AMY-2A/299-512) in *E. coli* BL21, and carried out Western blot analysis (Fig. 2A). Patient’s serum (A.O.) recognized the 30-kDa recombinant protein (line 1), but sera from healthy volunteers did not (lines 3 and 4). When the patient’s serum was preincubated with the recombinant protein, positive staining was abolished (line 2), suggesting that the autoantibody reacted with the recombinant protein, which contains the epitope.

Anti-human AMY-2A antibody produced in goat was bound to the *in vitro* translated $^{35}$S-AMY-2A, and was precipitated by protein G-sepharose (Fig. 2B). IgG from two patients with AIP also bound to the labeled protein and was precipitated, but the IgG from two healthy volunteers did not (Fig. 2B). This recombinant fluid phase autoantibody assay with *in vitro* transcription and translation of AMY-2A without additional amino acids, such as His-Tag, confirmed the specificity of the autoantibody against the protein.

Next, by coating the protein onto the plate, we developed an ELISA system for detecting anti-amylase antibodies in the serum. When compared to the normal serum, patient sera showed strong signals, which were well correlated with immunoprecipitated $^{35}$S-AMY-2A by protein G-sepharose (Fig. 2C). This positive reaction in ELISA was displaced in a concentration dependent fashion by AMY-2A/299-512 (Fig. 2D). When the AIP patient’s serum (A.O.) was diluted, we could detect positive signals up to $\times 1000$ dilution (Fig. 2E). To obtain a cut-off value for positivity, we carried out ROC analysis of the healthy volunteers (n = 100) and FT1DM patients (n = 17) (Fig. 2F). Table 2 shows criterion values and coordinates of the ROC curve. When the value was set as
34 (area under the ROC curve: 0.92, significance level P: 0.0001), sensitivity, specificity and positive predictive value were 88.24%, 99.00% and 93.7%, respectively.

**Prevalence of autoantibody against human AMY-2A in AIP patients.** Using the ELISA system, we determined the prevalence of autoantibody against human AMY-2A in AIP patients and various pancreatic diseases (Fig. 3). All 15 IgGs from patients with AIP were positive for AMY-2A/299-512, whereas 1 out of 100 IgGs from controls was positive for the antibody (p<0.001, Fisher’s exact test). All the IgGs from the patients with chronic alcoholic pancreatitis (n = 25) or with pancreas tumor (pancreatic cancer, n = 8; IPMT, n = 17) were negative for the antigen. Antibodies were detected in 9% (4/47) of patients with Hashimoto’s thyroiditis, a representative organ specific autoimmune disease (Fig. 3A).

Figure 3B shows the time course of the autoantibody titer from two AIP patients before and after PSL treatment. In patient A.O., IgG4 gradually increased and reached 5540 mg/dl, but administration of PSL initiated a rapid decrease of IgG4 to 571 mg/dl. Before PSL treatment, the titer of the autoantibody against AMY remained high, and PSL treatment induced a rapid decrease of the titer of AMY-2A autoantibody to a normal level. The fall rate of the antibody titer seemed to be parallel to that of serum IgG4. In patient T.M., administration of PSL also rapidly decreased the titer of the autoantibody against AMY. The autoantibodies did not increase even at the drug maintenance dose in both cases.

**Prevalence of autoantibody against human AMY-2A in patients with FT1DM and AT1DM.** We next studied the prevalence of autoantibody against human AMY-2A in various types of diabetic patients (FT1DM (n = 17), AT1DM (n = 42), and T2DM (n = 67) (Fig. 4). Interestingly, 88% of patients with FT1DM were positive for the autoantibody, but 1% of control was positive for the antibody (p<0.001, Fisher’s exact test). The autoantibody was detected with low frequency in patients with AT1DM (21%, 9/42), and patients with T2DM (6%, 4/67).

**DISCUSSION**

In 2002, Barera et al. reported a case of an 11-year-old girl with celiac disease and hypothyroidism. Because of hyperamylasemia, she was suspected to have chronic pancreatitis, but no pancreatic damage was demonstrated. By using ELISA to detect autoantibodies to amylase,
they found that she produced an autoantibody against porcine amylase, and that this declined after the institution of a gluten free diet (19).

In the present study, we also detected an autoantibody against pancreas-specific AMY-2A in all of the AIP patients, but not in patients with chronic alcoholic pancreatitis and with pancreatic tumors.

The presence of autoantibodies against CAII, LF, and pancreatic secretory trypsin inhibitor (PSTI) has been reported (3, 4, 20). However, the distribution of these molecules is non-organ-specific (21-23), and the prevalence of these autoantibodies against CAII, LF, and PSTI in AIP is rather low, ranging from 42 ~ 73% (3, 4, 20). Using 13 serum samples from our AIP patients, we carried out ELISA assays for autoantibodies against CAII and LF. As a result, 66% (10/15) were positive for CAII, and 53% (8/15) were positive for LF. Thus, an autoantibody against AMY-2A might be a more sensitive marker for AIP than that of CAII, LF, or PSTI.

Furthermore, the adoptive transfer of amylase-specific CD4+ T cells to rats was able to confer pancreatitis, while the transfer experiment with LF-specific or CAII-specific CD4+ T cells failed to induce experimental pancreatitis (24). Our findings of a high prevalence of autoantibody against AMY-2A in human AIP and the results from the adoptive transfer experiment of amylase-specific CD4+ T cells to rodents suggest that cellular and/or humoral autoimmunity against AMY-2A plays some role in the pathogenesis of AIP.

Approximately 80% of patients with chronic pancreatitis are alcoholic, the pathogenesis of which still remains unclear. However, it is well known that acute or chronic alcohol exposure suppresses all branches of the immune system (25), and indeed, none of our sera from patients with chronic alcoholic pancreatitis was positive for autoantibody against AMY-2A (Fig. 3). Therefore, an assay for autoantibody against AMY-2A is useful for distinguishing AIP from chronic alcoholic pancreatitis.

It is of particular interest that anti-AMY-2A autoantibody is detected in 88% of patients with FT1DM. FT1DM is a recently proposed subtype of type 1B, non-immune mediated or idiopathic type 1 diabetes (10, 11). A nationwide survey revealed that fulminant diabetes accounted for ~20% of Japanese type 1 DM with ketosis or ketoacidosis and flu-like symptoms frequently observed at onset (26). Clinical characteristics of this subtype of type 1 diabetes are 1) remarkably abrupt
onset of disease; 2) very short (<1 week) duration of diabetic symptoms; 3) severe ketoacidosis at diagnosis; 4) negative status of islet-related autoantibodies, such as GADAb and anti-IA-2 antibody; 5) virtually no C-peptide secretion (10 μg/day in urine); and 6) elevated serum pancreatic enzyme levels (27). These features, as well as the absence of insulitis in patients’ pancreases, have led some to hypothesize that an autoimmune mechanism dose not contribute to the development of FT1DM, but rather that viral infection plays a central role in the pathogenesis of the disease (28). However, we previously demonstrated CD4+ and CD8+ T cell infiltration to pancreatic exocrine cells as well as to the islet in an autopsy case deceased immediately after the onset of FT1DM (29).

Imagawa et al. also confirmed cellular infiltration of pancreatic islets in patients with FT1DM (28). Shimada et al. described an FT1DM patient with a high serum level of CXCL10, a chemokine that induces migration of activated T-cells to local lesions and GAD-reactive CD4+ cells in the periphery (30). These results, as well as the presence of an autoantibody against AMY-2A, suggest that the disease might be autoimmune-related, involving the exocrine as well as endocrine pancreas (11, 29).

Exocrine dysfunction and impaired glucose tolerance are common features for both AIP and FT1DM. With regard to the HLA genotype, Kawa et al. demonstrated that the DRB1*0405-DQB1*0401 haplotype is closely associated with AIP in the Japanese population (31), and Tanaka et al. revealed that the DQA1*0303-DQB1*0401 haplotype is strongly associated with FT1DM in an homologous manner (32). When we studied the frequency of this allele in our patients with AIP, five out of 15 patients were heterozygous for the DRB1*0405-DQB1*0401 haplotype. Although further study with larger sample sizes will be needed, these two reports, as well as our own analysis, suggest the importance of the DQB1*0401 allele in both diseases. Furthermore, we are able to detect autoantibody against AMY-2A in both with nearly the same prevalence. Although further investigation is needed, the present results suggest that, clinically and immunologically, AIP and FT1DM are closely related to one another.

**ACKNOWLEDGEMENTS**

The authors would like to acknowledge T. Hugh for his editorial work.
REFERENCES


21 Sly WS, Whyte MP, Sundaram V, Tashian RE, Hewett-Emmett D, Guibaud P,


Fig. 1  Cloning of human amylase α-2A cDNAs from λTriplEx2 human pancreas cDNA library.

Seven clones of human amylase α-2A cDNAs. Their lengths and 5’-ends are shown (A in ATG is designated as +1). The top bar indicates human amylase α-2A cDNA as reported by Wise et al. (11), and the common regions shared by all seven clones, from codons 299 to 512, are shown in the bottom bar.

Fig. 2  Western blot analysis and ELISA for detecting anti-human AMY-2A.

(A) Western blot analysis. Recombinant human AMY-2A (50 ng) from codons 299 to 512 (AMY-2A/299-512) was electrophoresed in 0.1% SDS–15% polyacrylamide and transferred onto a nitrocellulose filter. The filters reacted with serum (×1000) from an AIP patient (line 1) and normal control sera (lines 3 and 4). Line 2: AIP patient’s serum preincubated with 1 μg/ml of AMY-2A/299-512. MW: molecular weight markers. (B) Immunoprecipitation (IP) of [35S] AMY-2A with antibodies. [35S] AMY-2A was incubated with goat anti-amylase (line 1), normal goat IgG (line 2), sera from AIP patients (lines 3 and 4), and sera from healthy volunteers (lines 5 and 6), and then precipitated with protein G-sepharose. The pellets were electrophoresed in 0.1%
SDS-15% polyacrylamide, and analyzed with Bas 2000 image analyzer (Fujix, Tokyo, Japan). (C) Correlation between the result of ELISA and that of IP. By coating the recombinant human AMY-2A/299-512, we developed an ELISA system for detecting anti-human AMY-2A. Sera from 11 patients with AIP (●) and 2 normal controls (○) were assayed by ELISA and IP for detecting the autoantibody. (D) Absorption of positive ELISA signal with recombinant AMY-2A. One milliliter of a patient’s serum (1:500) was preincubated with the recombinant protein at the indicated dose overnight at 4 °C, and then the serum was used as the first antibody. The data are the mean of triplicate values. (E) Serum dilution experiment in ELISA assay. Positive serum from patient A.O. was diluted as indicated, and ELISA assay was carried out. The data are the mean of triplicate values. (F) ROC analysis of the healthy volunteers and FT1DM patients. We carried out ROC analysis of the healthy volunteers (n = 100) and FT1DM patients (n = 17) with MedCalc.
Fig. 3 Prevalence of autoantibody against human AMY-2A in patients with various pancreatic diseases

(A) Prevalence of autoantibody against human AMY-2A in patients with autoimmune pancreatitis (AIP, n = 15, ●), chronic alcoholic pancreatitis (CP, n = 25, ●), pancreatic tumor (PT, n = 25, ●), controls from healthy volunteers (C, n = 100, ●), and Hashimoto’s thyroiditis (n = 47, ●) was examined by ELISA, as described in the Methods. The data are the mean of triplicate values. The dotted line shows a cut-off value. Fisher’s exact test was carried out between AIP and control groups. *: p < 0.001.

(B) Time course of anti-AMY antibody and IgG4 of AIP patients. AIP patient (A.O.), whose IgG was used to screen λTriplEx2 human pancreas cDNA library, was treated with prednisolone (arrow). Before and after the treatment, anti-AMY antibody (●-●) and IgG4 (○-○) were measured. In the other AIP patient ((T.M), titer of the anti-AMY antibody (▲-▲) was also measured before and after PSL treatment (arrow).
Fig. 4  Prevalence of autoantibody against human AMY-2A in patients with various types of diabetes

Prevalence of autoantibody against human AMY-2A (●) in patients with fulminant type 1 diabetes (FT1DM, n = 17), acute onset type I (AT1DM, n = 42), type 2 diabetes (T2DM, n = 67), and controls from healthy volunteers (C, n = 100) was studied by ELISA, as described in the Materials and Methods. The data are the mean of triplicate values. The dotted line shows a cut-off value. Fisher’s exact test was carried out between FT1DM and control groups. *: p < 0.001.
### Table 1
Clinical Characteristics of Subjects

<table>
<thead>
<tr>
<th>Type of diabetes</th>
<th>N</th>
<th>Age (median) [95% CI]</th>
<th>Sex (M/F)</th>
<th>Duration* by insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune pancreatitis</td>
<td>15</td>
<td>66 [58 - 75]</td>
<td>14/1</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before PSL</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>After PSL</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic alcoholic pancreatitis</td>
<td>25</td>
<td>63 [53 - 70]</td>
<td>18/7</td>
<td>10</td>
</tr>
<tr>
<td>Pancreatic tumor</td>
<td>25</td>
<td>71 [63 - 73]</td>
<td>12/13</td>
<td>8</td>
</tr>
<tr>
<td>Cancer</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPMT</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulminant type 1 diabetes</td>
<td>17</td>
<td>40 [28 - 53]</td>
<td>14/3</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At onset***</td>
<td>13</td>
<td>0.76 ± 0.20**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>After onset</td>
<td>4</td>
<td>13.5 ± 2.38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute onset type 1 diabetes</td>
<td>42</td>
<td>25 [23 - 33]</td>
<td>14/28</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At onset***</td>
<td>22</td>
<td>0.7 ± 0.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>After onset</td>
<td>20</td>
<td>51.0 ± 50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>67</td>
<td>62 [58 - 65]</td>
<td>43/24</td>
<td>37</td>
</tr>
<tr>
<td>Hashimoto’s thyroiditis</td>
<td>47</td>
<td>60 [55 - 62]</td>
<td>6/41</td>
<td></td>
</tr>
<tr>
<td>Controls</td>
<td>100</td>
<td>47 [40 - 48]</td>
<td>59/41</td>
<td></td>
</tr>
</tbody>
</table>

PSL, prednisolone; IPMT, intraductal papillary mucinous tumor

* Duration; from the onset of diabetes to the time of sample collection

**Mean ± SD

***At onset; within 3 months after onset
Table 2
Criterion values and coordinates of the ROC curve

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>Positive predictive value</th>
<th>Negative predictive value</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;= 3.2</td>
<td>100.00 (80.3-100.0)</td>
<td>0.00 (0.0-3.7)</td>
<td>14.5</td>
<td></td>
</tr>
<tr>
<td>&gt; 11.4</td>
<td>100.00 (80.3-100.0)</td>
<td>9.00 (4.2-16.4)</td>
<td>15.7</td>
<td>100</td>
</tr>
<tr>
<td>&gt; 11.8</td>
<td>94.12 (71.2-99.0)</td>
<td>9.00 (4.2-16.4)</td>
<td>15.0</td>
<td>90.0</td>
</tr>
<tr>
<td>&gt; 17.3</td>
<td>94.12 (71.2-99.0)</td>
<td>53.00 (42.8-63.1)</td>
<td>25.4</td>
<td>98.1</td>
</tr>
<tr>
<td>&gt; 17.5</td>
<td>88.24 (63.5-98.2)</td>
<td>55.00 (44.7-65.0)</td>
<td>25.0</td>
<td>96.5</td>
</tr>
<tr>
<td>&gt; 34.0*</td>
<td>88.24 (63.5-98.2)</td>
<td>99.00 (94.5-99.8)</td>
<td>93.7</td>
<td>98.0</td>
</tr>
<tr>
<td>&gt; 34.7</td>
<td>82.35 (56.6-96.0)</td>
<td>99.00 (94.5-99.8)</td>
<td>93.3</td>
<td>97.1</td>
</tr>
<tr>
<td>&gt; 35.2</td>
<td>82.35 (56.6-96.0)</td>
<td>100.0 (96.3-100.0)</td>
<td>100.0</td>
<td>97.1</td>
</tr>
<tr>
<td>&gt; 98.4</td>
<td>0.00 (0.0-19.7)</td>
<td>100.0 (96.3-100.0)</td>
<td>85.5</td>
<td></td>
</tr>
</tbody>
</table>

Data in parenthesis are 95% CI, *: cut-off value for positivity